Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.1111/jfbc.13572
Journal or Publication Title: Journal of Food Biochemistry
Date: 2020
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.1111/jfbc.13572
ISSN: 0145-8884
Date Deposited: 07 Jan 2021 01:07
Abstract:

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. PRACTICAL APPLICATIONS: Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of Naringenin-loaded LCNs as an intervention would be of great interest to biological, formulation and respiratory scientists and clinicians.

Keywords: Naringenin; anti-inflammatory; liquid crystalline nanoparticles; lung cancer; migration; proliferation.

© 2020 Wiley Periodicals LLC.

Creators:
Creators
Email
Wadhwa, Ridhima
UNSPECIFIED
Paudel, Keshav Raj
UNSPECIFIED
Chin, Li Hian
UNSPECIFIED
Hon, Chian Ming
UNSPECIFIED
Madheswaran, Thiagarajan
UNSPECIFIED
Gupta, Gaurav
UNSPECIFIED
Panneerselvam, Jithendra
UNSPECIFIED
Lakshmi, Thangavelu
UNSPECIFIED
Singh, Sachin Kumar
UNSPECIFIED
Gulati, Monica
UNSPECIFIED
Dureja, Harish
UNSPECIFIED
Hsu, Alan
UNSPECIFIED
Mehta, Meenu
UNSPECIFIED
Anand, Krishnan
UNSPECIFIED
Devkota, Hari Prasad
UNSPECIFIED
Chellian, Jestin
UNSPECIFIED
Chellappan, Dinesh Kumar
UNSPECIFIED
Hansbro, Philip M.
UNSPECIFIED
Dua, Kamal
UNSPECIFIED
Last Modified: 07 Jan 2021 01:07
URI: https://eprints.centenary.org.au/id/eprint/934

Actions (login required)

View Item View Item